The potential effect of Ramadan fasting on musculoskeletal diseases: new perspectives

• Published in: Clinical rheumatology Vol. 40; no. 3; pp. 833 - 839
• Main Authors: Ben Nessib, Dorra, Maatallah, Kaouther, Ferjani, Hanene, Kaffel, Dhia, Hamdi, Wafa
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01-03-2021; Springer Nature B.V
• Subjects: Adipose Tissue; Arthritis; Body fat; Bone diseases; Clinical trials; Cytokines; Diet; Diurnal; Fasting; Gout; Humans; Inflammatory diseases; Islam; Leukocytes; Medicine; Medicine & Public Health; Metabolic syndrome; Musculoskeletal diseases; Osteoarthritis; Osteoporosis; Ramadan; Review Article; Rheumatic diseases; Rheumatoid arthritis; Rheumatology; Spondylarthritis; Drugs; Ramadan; Intermittent fasting; Rheumatic diseases
• DOI: 10.1007/s10067-020-05297-9
• EISSN: 1434-9949
• ISSN: 0770-3198

Ramadan, the ninth month of the Muslim lunar calendar, is a period of intermittent fasting alternated with moments of refeeding. The last decades have seen a growing number of reports that examine the potential effect of Ramadan intermittent fasting (RIF) on chronic musculoskeletal disorders. In this paper, we reviewed data that assessed the relationship of intermittent diurnal fasting during Ramadan with rheumatic diseases. Currently, recent evidence indicates that RIF may attenuate the inflammatory state by suppressing pro-inflammatory cytokine expression and reducing the body fat and the circulating levels of leukocytes. Therefore, it may be a promising non-pharmacological approach for managing the course of rheumatic inflammatory diseases. Despite differences between studies in daily fasting duration and dietary norms, there appears to be a consensus that most of the patients with rheumatoid arthritis (RA) or spondyloarthritis (SpA) who fasted Ramadan experienced relief of their symptoms. Nevertheless, further clinical trials are required to assess the effect of RIF on other musculoskeletal and bone disorders. Additionally, we evaluated the impact of RIF on chronic medication intake. Even if a few studies on this issue are available, the primary outcomes indicate that RIF does not significantly impair either compliance or tolerance to chronic medications. These findings may give some reassurance to patients with a specific fear of drug intake during this month.
Key Points
•
Intermittent diurnal fasting during Ramadan can modulate the inflammatory status through the down-regulation of metabolic syndrome, the reduction of pro-inflammatory cytokines, and the reduction of circulating levels of leukocytes
•
Ramadan intermittent fasting (RIF) can effectively improve the activity of rheumatic inflammatory diseases
.
•
Although further studies are still required, there seems no harm for patients with gout to participate in RIF
.
•
Primary outcomes indicate that RIF may be a promising non-pharmacological intervention for the management of patients with osteoarthritis and osteoporosis
.